JK Agri Genetics Board of Directors
Get the latest insights into the leadership at JK Agri Genetics. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Dr. Raghupati Singhania | Chairman |
| Mr. Vikrampati Singhania | Managing Director |
| Mrs. Swati Singhania | Director |
| Mr. Ajay Srivastava | Director |
| Mr. Raj Kumar Jain | Director |
| Mr. Kalpataru Tripathy | Director |
| Mr. Mudit Kumar | Director |
| Mr. Kuldeep Kumar Pandit | President & Director |
JK Agri Genetics Share price
JKAGRI
520.4
11.50 (-2.16%)Last updated on 4 Sep, 2025 | 15:45 IST
BUYSELL
Today's High
555.00
Today's Low
512.05
52 Week Low
312.00
52 Week High
559.90
The current prices are delayed, login to your account for live prices
LoginJK Agri Genetics FAQs
The board at JK Agri Genetics consists of experienced professionals, including Dr. Raghupati Singhania , Mr. Vikrampati Singhania , and others, overseeing the company’s strategic and corporate governance.
Directors at JK Agri Genetics are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Dr. Raghupati Singhania is the current chairman at JK Agri Genetics.
Executive directors at JK Agri Genetics are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, JK Agri Genetics adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At JK Agri Genetics, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.